他巴唑对Graves病患者血清可溶性白细胞介素-6受体的影响  

Effect of Methimazole on Serum Soluble Interleukin-6 Receptor in Patients with Graves Disease

作　　者：王加林[1] 赵亚平[1] 吴合军[1] 周玮 

机构地区：[1]江苏省淮阴市解放军第82医院内分泌科

出　　处：《标记免疫分析与临床》1999年第2期67-69,共3页Labeled Immunoassays and Clinical Medicine

摘　　要：５２例Ｇｒａｖｅｓ病（ＧＤ）患者随机分为两组，２６例接受他巴唑（ＭＭＩ），另２６例接受ＭＭＩ加心得安治疗。应用酶联免疫吸附分析（ＥＬＩＳＡ），测定了未治疗期（第０周）、部分缓解期（第２周）和缓解期（第６周）患者及２０名健康对照者血清可溶性白细胞介素－６受体（ｓＩＬ－６Ｒ）水平。结果表明：（１）ＭＭＩ和ＭＭＩ加心得安治疗的患者，未治疗期、部分缓解期血清ｓＩＬ－６Ｒ水平显著高于缓解期和健康对照组（Ｐ＜０．０１）；（２）ＭＭＩ与ＭＭＩ加心得安治疗患者各对应组的血清ｓＩＬ－６Ｒ水平无显著差异（Ｐ＞０．０５）；（３）ＧＤ患者血清ｓＩＬ－６Ｒ与游离Ｔ３（ＦＴ３）、游离Ｔ４（ＦＴ４）、促甲状腺素（ＴＳＨ）之间无显著相关。提示ＭＭＩ对ＧＤ患者血清ｓＩＬ－６Ｒ的产生具有抑制作用。Fifty-two patients with Graves disease(GD) were divided randomly into two groups.Twenty-six received methimazole(MMI) alone,another twenty-six received MMI plus propranolol.Serum soluble interleukin-6 receptor(sIL-6R) levels were determined using ELISA in 52 patients with GD at the 0wk(un-treatment),2wk(partial-remission),6wk(remission) and 20 healthy controls.The results showed:(1)in un-treatment and partial-remission Graves patients,serum sIL-6R levels of the MMI-treated group and MMI plus propranolol-treated group were much higher than those of healthy controls,respectively(P<0.01);(2)There were no differences in Serum sIL-6R levels between MMI-treated group and MMI plus propranolol-treated group;(3)Serum free T3,free T4 level in Graves patients had no correlation with serum sIL-6R.The results suggested that MMI should play the suppressive effect on the production of serum sIL-6R in Graves patients.

关 键 词：白细胞介素-6 受体 他巴唑 突眼性甲状腺肿 

分 类 号：R581.103[医药卫生—内分泌]